Are Fibroids Causing Your Symptoms?

What Are Uterine Fibroids?

Uterine fibroids (leiomyomas) are benign smooth-muscle tumors that grow within or on the wall of the uterus. They are not cancer, and fewer than 1 in 1,000 fibroids ever become malignant. Still, their physical size and location determine whether they produce symptoms severe enough to affect daily life.

Fibroids are classified by where they sit relative to the uterine wall:

• Submucosal fibroids bulge into the uterine cavity and most commonly cause heavy bleeding and fertility problems.
• Intramural fibroids are embedded within the muscular wall and are the most common type overall.
• Subserosal fibroids project outward toward the abdominal cavity and tend to cause bulk symptoms such as pelvic pressure or bladder compression.
• Pedunculated fibroids hang from a stalk attached to the uterus and can occasionally twist, causing acute pain.

How Common Are They?

The American College of Obstetricians and Gynecologists (ACOG) reports that fibroids affect up to 80% of women by age 50, though many women carry fibroids without ever knowing it. Epidemiological data published in the American Journal of Obstetrics and Gynecology show cumulative incidence by age 50 reaching 70% in white women and exceeding 80% in Black women. That racial disparity is not trivial: Black women are two to three times more likely to develop symptomatic fibroids and tend to present at younger ages with larger tumors.

Why Do Fibroids Grow?

Fibroids are estrogen-dependent and progesterone-sensitive. They rarely appear before puberty and typically shrink after menopause. Obesity raises circulating estrogen through peripheral aromatization of androgens in adipose tissue, which partly explains why higher body mass is a consistent risk factor. Vitamin D deficiency has also been identified as an independent risk factor in NIH-funded research.

The Core Symptoms of Uterine Fibroids

Not every fibroid announces itself. Roughly half of all women with ultrasound-confirmed fibroids report no symptoms at all. For those who do, symptoms depend heavily on fibroid number, size, and location within the uterus.

Heavy Menstrual Bleeding

Heavy or prolonged menstrual bleeding is the most reported fibroid symptom. Clinically, this is defined as blood loss exceeding 80 mL per cycle, though most women gauge severity by pad or tampon saturation and the presence of large clots.

A 2012 study in Fertility and Sterility (N=635) found that submucosal fibroids produced measurably greater menstrual blood loss than intramural or subserosal types. Chronic heavy bleeding can lead to iron-deficiency anemia, fatigue, and reduced quality of life. Hemoglobin levels below 10 g/dL are not unusual in women with large submucosal fibroids who go untreated for years.

Pelvic Pressure and Pain

A fibroid the size of a grapefruit compresses adjacent organs. Subserosal fibroids pressing on the bladder cause urinary frequency and urgency; those pushing posteriorly into the rectum cause constipation or a sensation of incomplete evacuation.

Pelvic pressure is distinct from acute pain. True acute pelvic pain from fibroids usually signals one of three events: torsion of a pedunculated fibroid, degeneration of a rapidly growing fibroid (common during pregnancy), or prolapse of a submucosal fibroid through the cervix. Each of these warrants prompt evaluation.

Dysmenorrhea and Dyspareunia

Fibroids distort the uterine architecture. That distortion generates stronger, more prolonged uterine contractions during menstruation, producing cramps disproportionate to cycle timing. Dyspareunia (pain during intercourse) is less commonly discussed but affects a significant minority of women with large intramural or posterior fibroids.

Low Back and Leg Pain

Large fibroids occasionally compress the sciatic nerve plexus or obstruct the ureters, causing referred pain down the back or legs. Ureteral compression, though uncommon, can silently impair kidney function and should be assessed with renal ultrasound when fibroids are confirmed to be very large (greater than 10 cm).

Who Is Most at Risk?

Several well-characterized risk factors increase the likelihood that fibroids will develop and become symptomatic.

Demographic and Hormonal Factors

Race carries the strongest independent risk. A cohort study published in the American Journal of Epidemiology confirmed that Black women develop fibroids at younger ages, with greater tumor burden, and with higher rates of surgical intervention than white women. Early menarche (before age 10), nulliparity, and a family history of fibroids each raise individual risk.

Exogenous hormones present a nuanced picture. Combined oral contraceptives do not appear to initiate fibroid growth, and low-dose formulations may reduce menstrual blood loss in women who already have fibroids. Medroxyprogesterone acetate (Depo-Provera) is associated with a reduced risk of fibroid development in some cohort data.

Lifestyle and Environmental Factors

Alcohol consumption, particularly beer, has been linked to elevated estrogen levels and higher fibroid risk in prospective data. High red meat intake and a diet low in fruits and vegetables may modestly raise risk. Emerging evidence from NIH-supported research points to hair relaxer use as a possible environmental contributor, an area of active investigation given its disproportionate relevance to Black women.

How Are Fibroids Diagnosed?

Pelvic Ultrasound: First-Line Imaging

Transvaginal ultrasound is the standard first-line test. It is widely available, free of radiation, and accurately identifies fibroids as small as 5 mm. The sensitivity for detecting submucosal fibroids improves further with saline infusion sonohysterography (SIS), a technique that instills sterile saline into the uterine cavity to outline lesions protruding into the lumen.

When MRI Changes the Picture

Magnetic resonance imaging (MRI) adds value when ultrasound findings are ambiguous, when the fibroid map is complex (multiple fibroids of varying sizes), or before minimally invasive procedures like uterine fibroid embolization (UFE) or MRI-guided focused ultrasound (MRgFUS). MRI reliably distinguishes fibroids from adenomyosis, a separate condition that mimics fibroid symptoms but requires different management.

Office Hysteroscopy

Direct visualization of the uterine cavity through hysteroscopy confirms submucosal involvement and allows same-session removal of small submucosal fibroids. Many practices now perform diagnostic hysteroscopy in-office under minimal anesthesia.

How Do Doctors Distinguish Fibroids From Other Causes?

Fibroid symptoms overlap with several other gynecologic and non-gynecologic conditions. A structured differential diagnosis prevents misattribution and delayed treatment.

HealthRX Fibroid Symptom Attribution Framework

| Symptom | Fibroid | Adenomyosis | Endometriosis | Polyps | Malignancy | |---|---|---|---|---|---| | Heavy bleeding | Yes, especially submucosal | Yes | Less common | Yes | Possible | | Dysmenorrhea | Moderate | Severe | Severe | Mild | Variable | | Pelvic pressure | Yes, bulk-related | Uterine only | Diffuse | Rare | Yes | | Infertility link | Submucosal strongest | Yes | Yes | Yes | Rare | | Ultrasound finding | Discrete mass | Diffuse wall thickening | Variable | Intracavitary | Irregular mass |

This framework guides clinical decision-making, but lab work also matters. A complete blood count checks for anemia secondary to blood loss. TSH rules out hypothyroidism, which independently causes heavy periods. CA-125 is generally unhelpful for fibroids but may be ordered when malignancy cannot be excluded clinically.

Medical Treatments for Fibroid Symptoms

Treatment selection depends on symptom severity, fibroid characteristics, desire for future fertility, and patient preference. No single therapy fits every case.

Hormonal Suppression

GnRH agonists such as leuprolide acetate (Lupron) create a temporary hypoestrogenic state that shrinks fibroids by 35 to 65% over three to six months. The tradeoff is a menopausal side-effect profile: hot flashes, bone loss, and vaginal dryness. Use beyond six months requires add-back estrogen/progestin therapy to protect bone density, per ACOG guidance.

Relugolix combination therapy (relugolix 40 mg / estradiol 1 mg / norethindrone acetate 0.5 mg, sold as Myfembree) received FDA approval in May 2021. The LIBERTY 1 and LIBERTY 2 trials (combined N=770) showed that 71.2% of women on Myfembree achieved the primary endpoint of reduced menstrual blood loss at 24 weeks versus 14.7% on placebo (P<0.001). This oral daily pill is approved for up to 24 months and avoids the bone-loss concerns of GnRH agonist monotherapy.

Levonorgestrel IUD and Oral Progestins

The levonorgestrel 52 mg IUD (Mirena) reduces menstrual blood loss by up to 90% in women with non-distorting fibroids. It does not shrink fibroids, but for women whose primary complaint is heavy bleeding rather than bulk symptoms, it can provide durable relief. Oral progestins (norethindrone acetate, medroxyprogesterone) are less effective but useful in women who cannot tolerate or access other options.

Tranexamic Acid

Tranexamic acid (Lysteda), a non-hormonal antifibrinolytic taken during menstruation at 1,300 mg three times daily for up to five days, reduces menstrual blood loss by approximately 40% in fibroid-related heavy bleeding. It is an option for women who prefer to avoid hormones or who are actively trying to conceive.

Procedural and Surgical Options

When medications fail or when fibroids are too large to respond adequately, procedural intervention becomes appropriate.

Uterine Fibroid Embolization (UFE)

UFE is a catheter-based procedure performed by interventional radiologists. Tiny particles are injected into the uterine arteries, cutting off blood supply to fibroids and causing them to shrink by 40 to 60% in volume. A landmark randomized trial published in the New England Journal of Medicine (N=157) showed that UFE produced equivalent symptom relief to hysterectomy at 2 years with shorter hospitalization and faster return to activity. UFE preserves the uterus but is generally not recommended as the primary approach for women who plan to conceive, as data on post-procedure fertility remain limited.

Myomectomy

Myomectomy removes individual fibroids while preserving the uterus. It can be performed hysteroscopically (for submucosal fibroids), laparoscopically, or via open abdominal surgery depending on fibroid size and accessibility. Hysteroscopic myomectomy improves fertility outcomes specifically for submucosal fibroids: a meta-analysis in Fertility and Sterility (17 studies, N=1,246) reported improved pregnancy rates after submucosal fibroid resection compared with untreated controls.

MRI-Guided Focused Ultrasound (MRgFUS)

MRgFUS uses focused ultrasound energy guided by real-time MRI to ablate fibroid tissue without incision. The FDA cleared this technology in 2004. It works best for women with a limited number of fibroids (typically one to three) measuring under 10 cm. Symptom relief is somewhat less durable than UFE or myomectomy, with up to 20% of patients requiring retreatment within two years.

Hysterectomy

Hysterectomy remains the only permanent cure for fibroids. It is the most commonly performed major gynecologic surgery in the United States, with fibroids accounting for approximately one-third of the 600,000 hysterectomies performed annually, according to CDC data. Minimally invasive laparoscopic or robotic approaches have largely replaced open abdominal hysterectomy for most patients, reducing recovery time from six weeks to two to three weeks.

Fibroids and Fertility: What the Evidence Shows

Subfertility from fibroids is location-dependent. Submucosal fibroids that distort the uterine cavity reduce implantation rates and increase miscarriage rates. The evidence for intramural fibroids is more contested: fibroids larger than 4 cm that do not distort the cavity may still reduce live birth rates, but the magnitude of effect is debated.

The ESHRE guideline on recurrent pregnancy loss recommends hysteroscopic removal of submucosal fibroids in women with recurrent miscarriage, citing improved subsequent live birth rates. For women undergoing IVF, the presence of a submucosal fibroid reduces live birth rates by approximately 50% compared with fibroid-free controls, based on pooled data from randomized and observational studies.

Intramural fibroids larger than 4 cm not affecting the cavity may reduce IVF success by 11 to 40% depending on the dataset. Whether surgical removal in this group improves outcomes remains an open research question.

When to See a Doctor Promptly

Some fibroid-related symptoms need same-day or next-day evaluation rather than a scheduled appointment. Seek prompt care for:

• Sudden, severe pelvic pain (may indicate torsion or degeneration)
• Passage of large clots with dizziness, rapid heart rate, or near-fainting (acute hemorrhage causing hemodynamic instability)
• Inability to urinate (fibroid compressing the urethra or bladder outlet)
• New onset of leg swelling and pain alongside a known large fibroid (possible inferior vena cava or iliac vein compression)

For ongoing but non-emergency symptoms such as progressively heavier periods, worsening pelvic pressure, or new bowel changes in a woman with known fibroids, scheduling an appointment within two to four weeks is appropriate. A hemoglobin check at that visit will determine whether iron replacement is needed before any procedure.

ACOG Practice Bulletin No. 228 states: "Women with symptomatic uterine leiomyomas should be offered a range of treatment options including medical management and procedural interventions, with treatment individualized based on the patient's symptoms, desire for future fertility, and preference for uterine preservation."

That guidance means no single treatment algorithm applies universally. The best path forward depends on your specific fibroid map, your hemoglobin level, your reproductive plans, and your tolerance for different side-effect profiles. Ask your clinician for a transvaginal ultrasound if you have unexplained heavy periods, pelvic pressure, or urinary frequency lasting more than two consecutive cycles. Hemoglobin below 11 g/dL in a premenopausal woman with heavy periods warrants fibroid evaluation even before symptoms become severe.